For research teamsHelp me find a study
Back to all studies
TerminatedEUCTR 2021-003834-34

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

SchizophreniaDrugFrom 18 Years to 50 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: EUCTR 2021-003834-34. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

EU CTR and ClinicalTrials.gov records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.

Recruitment status comes from the linked ClinicalTrials.gov record. Both registries list the identifiers for the same study.

View the historical EU CTR record

View the current ClinicalTrials.gov record

Historical EU CTR country statuses

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 7 sites
  • Neurocrine Clinical Site
    Pleven
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Plovdiv
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Sofia
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Sofia
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Sofia
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Sofia
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Sofia
    Site status: Not listed — confirm with the team
Czechia · 3 sites
  • Neurocrine Clinical Site
    Pilsen
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Prague
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Prague
    Site status: Not listed — confirm with the team
Serbia · 5 sites
  • Neurocrine Clinical Site
    Belgrade
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Gornja Toponica
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Kovin
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Kragujevac
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Niš
    Site status: Not listed — confirm with the team
Spain · 1 site
  • Neurocrine Clinical Site
    Madrid
    Site status: Not listed — confirm with the team
United States · 33 sites
  • Neurocrine Clinical Site
    Phoenix, Arizona
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Bentonville, Arkansas
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Bryant, Arkansas
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Anaheim, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Bellflower, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Glendale, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Oceanside, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Pico Rivera, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    San Diego, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    San Diego, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    San Rafael, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Stanford, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Torrance, California
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Aventura, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Okeechobee, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Pensacola, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Tampa, Florida
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Chicago, Illinois
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Ann Arbor, Michigan
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Flowood, Mississippi
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Cedarhurst, New York
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    New York, New York
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    New York, New York
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    DeSoto, Texas
    Site status: Not listed — confirm with the team
  • Neurocrine Clinical Site
    Houston, Texas
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What the source confirms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

What should you check before joining?

Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: December 7, 2021
Recruitment status
Terminated
Enrollment listed in the registry
216
Sponsor
Neurocrine Biosciences, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Czechia, ...
Age range
From 18 Years to 50 Years
Official registry ID
EUCTR 2021-003834-34
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop...
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: EUCTR 2021-003834-34. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What does the official source confirm?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Is this study recruiting?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

How can I check the participation requirements?

Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.